Cosentyx Wins FDA Approval for Polymyalgia Rheumatica Patients Who Cannot Taper Steroids, Doubling Sustained Remission in Trial
The FDA approved Cosentyx for adults with polymyalgia rheumatica who cannot taper steroids. In a phase 3 trial, the drug doubled sustained remission at one year versus placebo.
Medical Daily ·